Kernodle & Katon Asset Management Group’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Kernodle & Katon Asset Management Group’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$1K	Buy	+18	New	+$887	﹤0.01%	324

Other funds holding BIVV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Kernodle & Katon Asset Management Group's BIVV Position: Q1 2017 in Review

Kernodle & Katon Asset Management Group opened a new position in Bioverativ Inc. Common Stock (BIVV) in Q1 2017: 18 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #324 among its holdings.

467 funds tracked by Wall St. Rank hold BIVV as of Q1 2017.

Kernodle & Katon Asset Management Group held 18 shares of Bioverativ Inc. Common Stock worth $1K as of Q1 2017.
Bioverativ Inc. Common Stock was a new Kernodle & Katon Asset Management Group position in Q1 2017.
Bioverativ Inc. Common Stock made up ﹤0.01% of Kernodle & Katon Asset Management Group's portfolio in Q1 2017, its #324 holding.
467 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2017.

Based on Kernodle & Katon Asset Management Group's 13F filing for Q1 2017, filed 12 May 2017.